iRadimed (IRMD)
(Delayed Data from NSDQ)
$44.40 USD
-1.75 (-3.79%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $44.26 -0.14 (-0.32%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IRMD 44.40 -1.75(-3.79%)
Will IRMD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRMD
IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates
Acadia Healthcare (ACHC) Opens Facility to Serve California
IRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
UnitedHealth (UNH) Unit Awarded a Medicaid Contract by AHCCCS
Centene's (CNC) Ambetter Enhances Offerings With Broward Health
Centene (CNC) Wins Contract From Arizona's Medicaid Agency
Other News for IRMD
IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript
iRadimed price target lowered by $5 at Roth MKM, here's why
Iradimed (IRMD) Gets a Buy from Roth MKM
IRADIMED CORPORATION Announces Second Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
iRadimed Non-GAAP EPS of $0.42 beats by $0.06, revenue of $17.93M beats by $0.28M